The Complete Guide to Peptides

This guide is the starting point for the Info Center. It covers the science, the evidence tiers, the 2026 regulatory position and where to read more on each compound. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.

Peptides went from a niche corner of endocrinology to a consumer category in about five years, and the information environment did not keep up. Search almost any compound name and you'll find the same handful of claims copied across dozens of sites, usually traced back to one animal study that nobody links to. The gap between what has been demonstrated in humans and what gets asserted in marketing copy is, for most of these compounds, enormous.

This page is the orientation layer. It explains what these molecules are, why the delivery method is what it is, and — most usefully — how to sort the field by how much evidence actually sits behind each compound. Every section hands off to a deeper page rather than trying to be that page.

It assumes you're an adult capable of weighing a risk, and that you'd rather be told what isn't known than be sold a clean story.

What a peptide actually is

A peptide is a chain of amino acids — the same building blocks that make up proteins, just fewer of them, linked in a specific order. Your body manufactures thousands of them continuously. Insulin is a peptide. So are the hormones that tell your stomach it's full, your pituitary to release growth hormone, and your immune cells to move toward an infection.

The usual textbook line is that anything from two to about fifty amino acids is a peptide, and anything longer is a protein. That's a convention, not a law of chemistry, and it isn't the line that actually governs how these compounds are regulated.

The line that actually matters is 40

In the United States, the boundary is written into federal regulation. The FDA defines a protein as any alpha amino acid polymer with a defined sequence greater than 40 amino acids. Anything at or below that is not a protein for regulatory purposes — which means it travels the drug approval pathway (a New Drug Application) rather than the biologics pathway (a Biologics License Application). There's an exception that catches people out: a chemically synthesised polymer of 41 to 99 amino acids is still regulated as a drug, provided it was built by synthesis rather than grown in cells.

This isn't trivia. On 23 March 2020, insulin and a set of other protein products were formally deemed to be licensed biologics rather than approved drugs — the same molecules, reclassified overnight by statute. So when you read that there are "about 100 FDA-approved peptide drugs," treat the number as soft. What it means depends on where the writer drew the peptide/protein line and whether they counted before or after 2020. We've deliberately not put a headline number on this page, because the ones in circulation don't agree with each other and the definitional reason they disagree is more useful than any single figure.

How they work, briefly

Most therapeutic peptides work as signals rather than as raw material. They bind a receptor on a cell surface — the fit is specific, which is why a peptide can produce a large effect at a very small dose — and the cell responds. That specificity is the appeal of the category. It's also why peptides tend to have short half-lives: the body is built to clear signalling molecules quickly once the message has landed, and most unmodified peptides are broken down within minutes. Nearly every long-acting peptide medicine on the market is a natural sequence that's been deliberately modified to survive longer.

Why almost all of them are injected

Peptides are made of the same material as food protein, and your digestive system is extremely good at dismantling food protein. Swallow a peptide and stomach acid and gut enzymes take it apart before it reaches your bloodstream. What little survives still has to cross the intestinal wall, and peptides are generally too large and too water-loving to do that well.

The size of that problem is easiest to see in a drug where both routes exist. Semaglutide is sold both as a weekly injection and as a daily tablet, and the tablet needs an absorption enhancer just to work at all.

Here the two regulators who reviewed the same molecule published different numbers. The FDA's US prescribing information estimates the absolute bioavailability of oral semaglutide at roughly 0.4% to 1%. The European Medicines Agency's product information for the same drug gives approximately 1% to 2%. Neither is wrong exactly — these are population estimates with high variability between people — but the disagreement is a useful reminder that even well-studied numbers have error bars.

Run the arithmetic either way and the conclusion holds. The daily tablet's maintenance dose in the US is 14 mg, which is 98 mg across a week. At the FDA's midpoint absorption estimate, roughly 0.7 mg of that actually reaches the bloodstream — which is in the same range as the 1 mg that a typical weekly injection delivers directly. The pill contains something like a hundred times more drug than the injection, and it needs to, because the gut destroys almost all of it.

The practical read-across: an "oral" version of a research peptide that has not been formulated with a genuine absorption enhancer is mostly a way of selling powder that your stomach will digest. That's the reasoning behind why peptide injections are better than pills. If you're new to the mechanics, how to reconstitute peptides and dosing and injection basics cover the practical side.

The evidence ladder

This is the most useful thing on the page. Compounds sold under the single word "peptide" sit at wildly different distances from proven. Sorting them into rungs makes the marketing much easier to read, because almost every overclaim you'll encounter works by borrowing the credibility of a higher rung for a compound sitting on a lower one.

Two things this framing makes visible. First, "not FDA approved" covers rungs two through five, which are wildly different situations — sermorelin's status and BPC-157's status have almost nothing in common. Second, the healing peptides with the loudest reputations sit on the bottom rung. That doesn't make them useless. It makes the confident percentage claims about them unsupported, which is a different problem.

The main categories

The site is organised around what people are actually trying to do. Each card below is an entry point rather than a summary.

Metabolic & weight

The most evidence-backed category by a wide margin, because it contains approved medicines with large phase 3 programmes behind them. GLP-1 and dual or triple agonists reduce appetite and slow gastric emptying. They also carry real risks — gastrointestinal effects, gallbladder problems, pancreatitis signals, and meaningful loss of lean mass alongside fat if protein intake and resistance training don't keep up.

One caution that belongs here rather than in a footnote: appetite suppression is a powerful tool and a poor master. If tracking weight or intake starts to feel compulsive, or the goal keeps moving downward regardless of what the scale says, that's worth raising with a doctor rather than solving with a higher dose.

Healing & recovery

The category with the biggest gap between reputation and human evidence. BPC-157 and TB-500 have genuinely interesting animal work behind them and almost no controlled human data. Both are angiogenic — they promote new blood vessel growth — which is why a cancer history is a serious consideration and why timing around surgery is a conversation for your surgeon, not a forum.

Growth hormone & anti-aging

Secretagogues prompt your own pituitary to release growth hormone in pulses, rather than replacing it. That's a real mechanistic difference from injected HGH, and it's the honest basis for the category. Blood sugar and insulin sensitivity are the risks that matter most here.

Cognitive & sleep

Mostly Russian-developed compounds with domestic clinical use and little Western replication — rung four territory. Worth saying plainly: poor sleep, low mood and difficulty concentrating are also how sleep apnoea, thyroid disease, anaemia, iron or B12 deficiency, depression and anxiety disorders present. Those are diagnosable and treatable, and no peptide substitutes for finding out which one you have. Get assessed first.

Specialty

Everything that doesn't fit the categories above: sexual health, mitochondrial function, immune modulation, pigmentation. Evidence quality varies more within this group than any other.

What "research use only" means

This phrase does a lot of work and is widely misunderstood. It does not mean a compound is illegal, and it does not mean it has been assessed and cleared. It means no regulator has evaluated it as a medicine for human use, so it can be sold for laboratory purposes but not marketed with therapeutic claims.

The United States, and what changed in 2026

The FDA's position on several research peptides shifted this year, and it's being widely overstated online. On 15 April 2026 the agency removed twelve peptide bulk substances from Category 2 of its 503A list — the category for substances it considers to present significant safety risks — after the underlying nominations were withdrawn. The twelve were BPC-157, Cathelicidin (LL-37), Dihexa acetate, Emideltide (DSIP), Epitalon, GHK-Cu (injectable routes), KPV, PEG-MGF, Melanotan II, MOTS-C, Semax and Thymosin Beta-4 fragment (TB-500).

Removal from Category 2 is not approval, and it does not by itself make these substances eligible for compounding. It moved them into a review process. The FDA's Pharmacy Compounding Advisory Committee met on 23–24 July 2026 to consider whether they should be added to the 503A bulk drug substances list, with a further review scheduled before February 2027. No final determinations had been announced as of this writing. Even the most favourable outcome would permit prescription compounding through licensed pharmacies — not over-the-counter sale, and not the same thing as an approved drug.

Europe and Costa Rica

The European Medicines Agency has not approved any of the research compounds discussed on this site. In Costa Rica, peptides are not controlled substances under Ley N° 8204. Under the Ley General de Salud (Ley N° 5395), the Ministerio de Salud requires registro sanitario before any medicine may be commercially marketed or imported — which registered peptide medicines such as semaglutide and somatropin have, and unregistered research compounds do not. Registered medicines require a prescription and are dispensed through licensed pharmacies. Costa Rican customs rules permit medicines carried in personal baggage in quantities appropriate to the traveller's own needs, and the Ministerio de Salud operates a personal-import pathway that requires clinical justification from your physician. The detail is covered in are peptides illegal in Costa Rica and the Costa Rica FAQ.

Sport

Section S0 of the World Anti-Doping Agency's 2026 Prohibited List prohibits, at all times, "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." That sentence covers essentially every research peptide, whether or not it appears by name — the list uses BPC-157 as a worked example. Growth hormone secretagogues are separately prohibited under S2. If you compete under anti-doping rules, assume prohibited until you have verified otherwise.

For the fuller treatment of what separates a research compound from a pharmaceutical one, see research peptides vs pharmaceutical peptides and are peptides safe — what the research says.

Quality, purity and storage

Because these compounds are sold outside pharmaceutical regulation, what's in the vial is determined by the supplier's own standards. A certificate of analysis is the main instrument you have, and it's worth understanding exactly what one proves: that a tested sample from a given batch had a stated identity and purity. It does not prove that your individual vial matches, and it is only as trustworthy as the lab that issued it and the vendor that published it.

Where to start if you're new

In order, and none of these steps is optional if you intend to do this properly.

It's also worth knowing what these compounds are not. Peptides vs SARMs vs steroids and natural vs synthetic peptides clear up the two comparisons people arrive with most often.

What outperforms every peptide here

This section costs us sales and stays on the page anyway, because it's true and because a reader who finds out later feels lied to.

Sleep. Seven to nine hours, consistently, changes recovery, appetite regulation, mood, cognition and hormonal output more reliably than anything on this site. Untreated sleep apnoea in particular will defeat any peptide protocol you care to run, and it's common, diagnosable and treatable.

Protein and resistance training. Adequate protein plus progressive resistance training is the only intervention that reliably preserves lean mass — during weight loss, during ageing, after injury. No peptide substitutes for it, and several categories work considerably better alongside it.

An actual diagnosis. If something is wrong, finding out what is worth more than any compound. Thyroid disease, iron deficiency, low testosterone, depression, sleep disorders and a dozen other conditions produce exactly the symptoms people buy peptides to fix, and they have established treatments that work.

An approved medicine, properly prescribed. If your goal falls within what an approved drug already treats, the approved version — prescribed, monitored, and manufactured under pharmaceutical regulation — is a better option than the research-grade equivalent. That's true even though we sell the research-grade equivalent.

Common Questions

Important disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. Of the compounds named on this page, semaglutide, tirzepatide, tesamorelin and bremelanotide (PT-141) hold FDA approval for specific named indications; sermorelin held FDA approval as Geref until its commercial discontinuation in 2008; thymosin alpha-1 is approved in more than 35 countries but not by the FDA; and the remaining compounds discussed — including BPC-157, TB-500, KPV, MOTS-C, Epithalon, Semax, Selank, DSIP, GHK-Cu, SS-31 and Melanotan II — are not approved as pharmaceutical drugs by the FDA, the European Medicines Agency, or Costa Rica's Ministerio de Salud, and are sold for laboratory and research purposes only. The FDA's April and July 2026 actions concerning twelve peptide bulk substances are steps within a compounding review process and do not constitute approval; no final determination had been made at the time of writing. Dose figures on this page describe what appears on approved product labels and in published research; they are not endorsements of those doses for any specific individual, and no dose has been validated for any individual. Several compounds referenced carry specific contraindications — including a personal or family history of cancer for angiogenic compounds, and pregnancy — and several affect blood sugar, blood pressure, or clotting. Most substances discussed fall under Section S0 of the World Anti-Doping Agency's Prohibited List; athletes should verify status individually before use. Always consult a qualified healthcare professional before beginning any peptide protocol. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.